TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
SPRY

ARS Pharmaceuticals, Inc

Healthcare · Biotechnology · —

4.40$ +5.8% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Balance Sheet

ARS Pharmaceuticals, Inc (SPRY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 249 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet SPRY
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
249 233 228 222 218 351 327 313 373 328 288 249
244 232 226 221 209 334 304 281 339 285 245 212
61 71 56 37 40 51 40 52 60 41 24 8.2
242 228 224 219 205 314 276 240 288 245 201 144
0.8 0.8 0.6 0.5 1.2 9.2 10 26 38 26 29 47
-0.8 0.0 0.7 5.2 7.3 8.7 7.8 8.4 8.8 12
0.7 0.6 0.5 0.4 7.9 7.7 7.5 13 15 14 14 14
11 2.4 3.7 6.7 17 94 98 121 225 213 226 237
11 2.4 3.7 6.7 17 23 28 46 51 39 50 61
0.2 0.2 0.2 0.2 0.1 0.0 0.1 0.6 0.6 0.6 0.6
3.0 0.8 0.8 3.3 8.3 9.9 4.1 16 8.4 5.7 4.7 60
96 96 97 97
237 231 224 215 201 257 229 192 148 114 61 13
-124 -131 -142 -154 -173 -123 -157 -202 -253 -295 -355 -418
96 96 96 97 97 98 98 98 99 99 99 99

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?